首页 > 最新文献

Saudi Pharmaceutical Journal最新文献

英文 中文
Impacts of Anabolic-androgenic steroid supplementation on female health and offspring: Mechanisms, side effects, and medical perspectives 合成代谢雄性类固醇补充剂对女性健康和后代的影响:机制、副作用和医学视角
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-22 DOI: 10.1016/j.jsps.2024.102205
Beatriz Menegate Santos , Jessica Peres Alves de Souza , Luísa Rodrigues de Paula Goulart , Jéssica Castro Pereira Petrine , Fernando Henrique Ferrari Alves , Bruno Del Bianco-Borges
The increasing prevalence of Anabolic–androgenic steroids (AAS) among women, driven by the pursuit of improved body aesthetics, characterized by higher lean mass and reduced adipose tissue, raises significant health concerns, particularly due to the limited knowledge regarding their effects on the female organism. Prolonged use and/or high doses of AAS are linked to various harmful side effects, including mood changes, psychiatric disorders, voice deepening, clitoromegaly, menstrual irregularities, and cardiovascular complications, prompting medical societies to discourage their widespread use due to insufficient evidence supporting their safety and efficacy. Studies in female rodents have shown that AAS can lead to increased aggression, inflammation, reduced neuronal density, and negative impacts on the myocardium and blood vessels. Additionally, maternal administration of androgens during pregnancy can adversely affect offspring’s reproductive, neuronal, and metabolic health, resulting in long-term impairments. The complexity of the mechanisms underlying AAS effects, and their potential genotoxicity remains poorly understood. This review aims to elucidate the various ways in which AAS can impact female physiology and that of their offspring, highlight commonly used anabolic substances, and discuss the positions of medical societies regarding AAS use.
女性越来越普遍地使用合成代谢雄性类固醇(AAS),这是由于她们追求以增加瘦体重和减少脂肪组织为特征的身体美感,这引起了人们对健康的极大关注,特别是由于人们对其对女性机体的影响了解有限。长期使用和(或)高剂量的 AAS 与各种有害的副作用有关,包括情绪变化、精神失常、声音加深、阴蒂肥大、月经不调和心血管并发症,由于没有足够的证据支持其安全性和有效性,医学协会不鼓励广泛使用。对雌性啮齿动物的研究表明,AAS 可导致攻击性增强、炎症、神经元密度降低以及对心肌和血管的负面影响。此外,母体在怀孕期间服用雄激素会对后代的生殖、神经元和新陈代谢健康产生不利影响,导致长期损害。人们对 AAS 作用机制的复杂性及其潜在的基因毒性仍然知之甚少。本综述旨在阐明 AAS 影响女性及其后代生理机能的各种方式,重点介绍常用的同化物质,并讨论医学会对使用 AAS 的立场。
{"title":"Impacts of Anabolic-androgenic steroid supplementation on female health and offspring: Mechanisms, side effects, and medical perspectives","authors":"Beatriz Menegate Santos ,&nbsp;Jessica Peres Alves de Souza ,&nbsp;Luísa Rodrigues de Paula Goulart ,&nbsp;Jéssica Castro Pereira Petrine ,&nbsp;Fernando Henrique Ferrari Alves ,&nbsp;Bruno Del Bianco-Borges","doi":"10.1016/j.jsps.2024.102205","DOIUrl":"10.1016/j.jsps.2024.102205","url":null,"abstract":"<div><div>The increasing prevalence of Anabolic–androgenic steroids (AAS) among women, driven by the pursuit of improved body aesthetics, characterized by higher lean mass and reduced adipose tissue, raises significant health concerns, particularly due to the limited knowledge regarding their effects on the female organism. Prolonged use and/or high doses of AAS are linked to various harmful side effects, including mood changes, psychiatric disorders, voice deepening, clitoromegaly, menstrual irregularities, and cardiovascular complications, prompting medical societies to discourage their widespread use due to insufficient evidence supporting their safety and efficacy. Studies in female rodents have shown that AAS can lead to increased aggression, inflammation, reduced neuronal density, and negative impacts on the myocardium and blood vessels. Additionally, maternal administration of androgens during pregnancy can adversely affect offspring’s reproductive, neuronal, and metabolic health, resulting in long-term impairments. The complexity of the mechanisms underlying AAS effects, and their potential genotoxicity remains poorly understood. This review aims to elucidate the various ways in which AAS can impact female physiology and that of their offspring, highlight commonly used anabolic substances, and discuss the positions of medical societies regarding AAS use.</div></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 12","pages":"Article 102205"},"PeriodicalIF":3.0,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bioadhesive hybrid system of niosomes and pH sensitive in situ gel for itraconazole ocular delivery: Dual approach for efficient treatment of fungal infections 用于伊曲康唑眼部给药的niosomes和pH敏感原位凝胶生物黏附混合系统:高效治疗真菌感染的双重方法
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-22 DOI: 10.1016/j.jsps.2024.102208
Mohamed M. Badran , Areej Alsubaie , Mounir M. Salem Bekhit , Abdullah H. Alomrani , Aliyah Almomen , Mohamed Abbas Ibrahim , Doaa Hasan Alshora
Itraconazole (ITZ) is a highly effective antifungal agent. However, its oral application is associated with systemic toxicity and poor topical use. The present study aims to improve the antifungal activity of ITZ by loading it into bioadhesive niosomes. This approach is considered to enhance the ocular permeation of ITZ, thereby boosting its efficacy against fungal infections. Therefore, it was encapsulated into niosomes (F1) and subsequently coated with hyaluronic acid (HA; F2), chitosan (CS; F3), or a bilayer of CS/HA (F4). In addition, they were further incorporated into pH-sensitive in situ gels. This dual approach is expected to increase the amount of corneal-permeated ITZ, facilitating more effective management of ocular fungal infection.
Firstly, the niosomes were prepared by hydrating proniosomes using span 60, cholesterol, and phospholipid. ITZ-niosomes showed an increase in vesicle size from 165.5 ± 3.4 (F1) to 378.2 ± 7.2 nm (F3). The zeta potential varied within −20.9 ± 2.1 (F1), −29.5 ± 3.1 (F2), 32.3 ± 1.9 (F3), and 22.6 ± 1.3 mV (F4). The high EE% values ranged from 78.1 ± 2.2 % to 86.6 ± 2.9 %. Regarding ITZ release, F1 demonstrated a high release profile, whereas bioadhesive niosomes showed sustained release patterns. Furthermore, in situ gels containing niosomes displayed excellent gelling capacity and viscosity. Remarkably, F3 laden-in situ gels (F3-ISG) demonstrated the highest ex vivo corneal permeability of ITZ and antifungal activity with a safety effect. These results indicate that F3-ISG presents a promising strategy for boosting the ocular delivery of ITZ, that could help in treating ocular fungal infections.
伊曲康唑(ITZ)是一种高效的抗真菌剂。然而,其口服应用具有全身毒性,局部使用效果不佳。本研究旨在通过将伊曲康唑装入生物粘附性iosomes 来提高其抗真菌活性。这种方法被认为能增强 ITZ 的眼部渗透,从而提高其对真菌感染的疗效。因此,先将 ITZ 包封在 niosomes(F1)中,然后用透明质酸(HA;F2)、壳聚糖(CS;F3)或 CS/HA 双层(F4)包覆。此外,它们还被进一步加入对 pH 值敏感的原位凝胶中。这种双重方法有望增加角膜渗透 ITZ 的数量,从而更有效地治疗眼部真菌感染。首先,使用 span 60、胆固醇和磷脂水合原代物,制备出了新生物体。ITZ-niosomes的囊泡尺寸从165.5 ± 3.4(F1)增至378.2 ± 7.2 nm(F3)。zeta 电位在 -20.9 ± 2.1 (F1)、-29.5 ± 3.1 (F2)、32.3 ± 1.9 (F3) 和 22.6 ± 1.3 mV (F4) 范围内变化。高 EE% 值从 78.1 ± 2.2 % 到 86.6 ± 2.9 % 不等。在 ITZ 释放方面,F1 显示出较高的释放曲线,而生物黏附性iosomes 则显示出持续释放模式。此外,含有niosomes的原位凝胶显示出优异的胶凝能力和粘度。值得注意的是,含有 F3 的原位凝胶(F3-ISG)显示出最高的 ITZ 体内外角膜渗透性和抗真菌活性,并具有安全效应。这些结果表明,F3-ISG 是促进 ITZ 眼部给药的一种有前途的策略,有助于治疗眼部真菌感染。
{"title":"Bioadhesive hybrid system of niosomes and pH sensitive in situ gel for itraconazole ocular delivery: Dual approach for efficient treatment of fungal infections","authors":"Mohamed M. Badran ,&nbsp;Areej Alsubaie ,&nbsp;Mounir M. Salem Bekhit ,&nbsp;Abdullah H. Alomrani ,&nbsp;Aliyah Almomen ,&nbsp;Mohamed Abbas Ibrahim ,&nbsp;Doaa Hasan Alshora","doi":"10.1016/j.jsps.2024.102208","DOIUrl":"10.1016/j.jsps.2024.102208","url":null,"abstract":"<div><div>Itraconazole (ITZ) is a highly effective antifungal agent. However, its oral application is associated with systemic toxicity and poor topical use. The present study aims to improve the antifungal activity of ITZ by loading it into bioadhesive niosomes. This approach is considered to enhance the ocular permeation of ITZ, thereby boosting its efficacy against fungal infections. Therefore, it was encapsulated into niosomes (F1) and subsequently coated with hyaluronic acid (HA; F2), chitosan (CS; F3), or a bilayer of CS/HA (F4). In addition, they were further incorporated into pH-sensitive <em>in situ</em> gels. This dual approach is expected to increase the amount of corneal-permeated ITZ, facilitating more effective management of ocular fungal infection.</div><div>Firstly, the niosomes were prepared by hydrating proniosomes using span 60, cholesterol, and phospholipid. ITZ-niosomes showed an increase in vesicle size from 165.5 ± 3.4 (F1) to 378.2 ± 7.2 nm (F3). The zeta potential varied within −20.9 ± 2.1 (F1), −29.5 ± 3.1 (F2), 32.3 ± 1.9 (F3), and 22.6 ± 1.3 mV (F4). The high EE% values ranged from 78.1 ± 2.2 % to 86.6 ± 2.9 %. Regarding ITZ release, F1 demonstrated a high release profile, whereas bioadhesive niosomes showed sustained release patterns. Furthermore, <em>in situ</em> gels containing niosomes displayed excellent gelling capacity and viscosity. Remarkably, F3 laden-<em>in situ</em> gels (F3-ISG) demonstrated the highest <em>ex vivo</em> corneal permeability of ITZ and antifungal activity with a safety effect. These results indicate that F3-ISG presents a promising strategy for boosting the ocular delivery of ITZ, that could help in treating ocular fungal infections.</div></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 12","pages":"Article 102208"},"PeriodicalIF":3.0,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective 巴利昔尼治疗斑秃的预算影响分析:沙特医院的视角
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-08 DOI: 10.1016/j.jsps.2024.102204
A. Alshahrani , S. Al-Aqeel , M. Alshahrani , S. Alqahtani , S.T. Alhawwashi , M.S. Al-Nasser , M. Zaitoun

Objectives

To perform a budget impact analysis (BIA) of the adoption of baricitinib for the management of alopecia areata (AA) by a Saudi public sector payer.

Methods

A BIA model was developed to calculate the expected financial impact under two scenarios: the baseline scenario, which reflects the current mix of treatments without baricitinib, and the projected scenario, in which baricitinib is adopted. The model assumed that patients with severe AA and those with mild-to-moderate AA who did not respond to other treatments were eligible for baricitinib treatment. The model input was based on published evidence, expert opinions, and the Saudi Expert Consensus Statement on the Diagnosis and Management of AA.

Results

Assuming a hypothetical total eligible population of 368 patients received different AA treatments over the 12-months study period. The aggregated 5-years cost in the baseline scenario was SR 5,836,616. Upon the introduction of baricitinib as an alternative treatment for severe AA, the projected aggregated budget impact was SR 7,473,138. Sensitivity analysis showed that the results were most sensitive to AA prevalence, percentage of severe AA, and predicted market share for baricitinib over the 5-year time horizon.

Conclusion

The addition of baricitinib to formularies is likely to increase the cost impact from a government hospital perspective. However, this addition expands the treatment options for patients with AA and may result in improved outcomes. Future cost-effectiveness analyses are recommended to estimate the cost per incremental improvement in the outcomes.
方法建立了一个预算影响分析模型,以计算两种情况下的预期财务影响:基线情况(反映了目前没有巴利替尼的治疗组合)和预测情况(采用巴利替尼)。该模型假设重度 AA 患者和对其他治疗无效的轻度至中度 AA 患者有资格接受巴利替尼治疗。模型输入基于已发表的证据、专家意见和《沙特 AA 诊断和管理专家共识声明》。结果假设符合条件的总人数为 368 人,在 12 个月的研究期内接受了不同的 AA 治疗。基线方案的 5 年总费用为 5,836,616 沙特里亚尔。在引入巴利替尼作为重症 AA 的替代治疗方法后,预计的预算影响总额为 7,473,138 沙特里亚尔。敏感性分析表明,结果对 AA 患病率、严重 AA 的百分比以及巴利替尼在 5 年时间跨度内的预测市场份额最为敏感。不过,这增加了 AA 患者的治疗选择,可能会改善治疗效果。建议今后进行成本效益分析,以估算疗效每增加一项改善所需的成本。
{"title":"Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective","authors":"A. Alshahrani ,&nbsp;S. Al-Aqeel ,&nbsp;M. Alshahrani ,&nbsp;S. Alqahtani ,&nbsp;S.T. Alhawwashi ,&nbsp;M.S. Al-Nasser ,&nbsp;M. Zaitoun","doi":"10.1016/j.jsps.2024.102204","DOIUrl":"10.1016/j.jsps.2024.102204","url":null,"abstract":"<div><h3>Objectives</h3><div>To perform a budget impact analysis (BIA) of the adoption of baricitinib for the management of alopecia areata (AA) by a Saudi public sector payer.</div></div><div><h3>Methods</h3><div>A BIA model was developed to calculate the expected financial impact under two scenarios: the baseline scenario, which reflects the current mix of treatments without baricitinib, and the projected scenario, in which baricitinib is adopted. The model assumed that patients with severe AA and those with mild-to-moderate AA who did not respond to other treatments were eligible for baricitinib treatment. The model input was based on published evidence, expert opinions, and the Saudi Expert Consensus Statement on the Diagnosis and Management of AA.</div></div><div><h3>Results</h3><div>Assuming a hypothetical total eligible population of 368 patients received different AA treatments over the 12-months study period. The aggregated 5-years cost in the baseline scenario was SR 5,836,616. Upon the introduction of baricitinib as an alternative treatment for severe AA, the projected aggregated budget impact was SR 7,473,138. Sensitivity analysis showed that the results were most sensitive to AA prevalence, percentage of severe AA, and predicted market share for baricitinib over the 5-year time horizon.</div></div><div><h3>Conclusion</h3><div>The addition of baricitinib to formularies is likely to increase the cost impact from a government hospital perspective. However, this addition expands the treatment options for patients with AA and may result in improved outcomes. Future cost-effectiveness analyses are recommended to estimate the cost per incremental improvement in the outcomes.</div></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 12","pages":"Article 102204"},"PeriodicalIF":3.0,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia 在沙特阿拉伯,evolocumab 对原发性高胆固醇血症和混合型血脂异常的实际安全性和有效性
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-04 DOI: 10.1016/j.jsps.2024.102203
Abdulaali R. Almutairi , Walaa A. Alshahrani , Ghaida K. Alhathlol , Fatimah Alsheikh , Abdulaziz Alakeel , Majed S. Al Yami , Mohammad Fouda , Omar A. Almohammed , Meshal S. Alhamed , Awatif Hafiz , Hussam Kutbi , Alaa Bagalagel , Aisha Alharbi , Mashael Alaboud , Sarah Aljohani , Waddah Ashram

Introduction

Evolocumab’s short-term efficacy and safety were proven in phase-3 clinical trial, but its long-term safety and effectiveness in the Saudi population are yet to be studied. The aim of this study was to assess the long-term safety and effectiveness of evolocumab in Saudi patients with primary hypercholesterolemia or mixed dyslipidemia.

Method

A retrospective cohort study evaluated adult patients who had newly been prescribed evolocumab for hypercholesterolemia or mixed dyslipidemia. Safety events included myocardial infarction, unstable angina, stroke, transient ischemic attack, heart failure, rhabdomyolysis, renal dysfunction, and myalgia. Effectiveness outcomes included changes in lipid profiles from baseline, assessed at 6-, 12-, 18-, and 24-month.

Results

The study sample were 469 who newly prescribed evolocumab, from which 69.1 % being male, were included. The most prevalent comorbidities were coronary artery disease, diabetes, and hypertension. Statin was the most commonly used therapy. The most common adverse events at 6-month follow-up, based on the incidence rate per 1000 person-years, were coronary revascularization (63.20), myalgia (44.96), myocardial infarction (31.53), unstable angina (31.49), heart failure (26.94), rhabdomyolysis without renal dysfunction (8.93), transient ischemic attack (4.46), and rhabdomyolysis with renal dysfunction (4.46). Stroke incidence increased with follow-up length, from 8.87 per 1000 person-years at 6 months to 12.84 per 1000 person-years at 24 months. Evolocumab use significantly reduced LDL and total cholesterol levels at 6, 12, 18, and 24 months follow-up, while having no significant effect on HDL or triglycerides levels.

Conclusion

Evolocumab appeared to be safe and effective therapeutic option for patients with primary hypercholesterolemia or mixed dyslipidemia to potentially reduce LDL levels to therapeutic levels when statins are insufficient.
导言依维莫司单抗的短期疗效和安全性已在第三阶段临床试验中得到证实,但其在沙特人群中的长期安全性和有效性仍有待研究。本研究旨在评估 evolocumab 在沙特原发性高胆固醇血症或混合型血脂异常患者中的长期安全性和有效性。安全性事件包括心肌梗死、不稳定型心绞痛、中风、短暂性脑缺血发作、心力衰竭、横纹肌溶解症、肾功能障碍和肌痛。疗效结果包括血脂状况与基线相比的变化,分别在6个月、12个月、18个月和24个月进行评估。最常见的合并症是冠心病、糖尿病和高血压。他汀类药物是最常用的疗法。根据每千人年的发病率,随访6个月时最常见的不良事件是冠状动脉血运重建(63.20)、肌痛(44.96)、心肌梗死(31.53)、不稳定型心绞痛(31.49)、心力衰竭(26.94)、无肾功能障碍的横纹肌溶解(8.93)、短暂性脑缺血发作(4.46)和伴有肾功能障碍的横纹肌溶解(4.46)。中风发病率随着随访时间的延长而增加,从6个月时的每1000人年8.87例增加到24个月时的每1000人年12.84例。结论对于原发性高胆固醇血症或混合型血脂异常患者来说,使用伊沃洛单抗似乎是一种安全有效的治疗选择,当他汀类药物不足以降低低密度脂蛋白水平至治疗水平时,伊沃洛单抗有可能降低低密度脂蛋白水平至治疗水平。
{"title":"Real-World safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia","authors":"Abdulaali R. Almutairi ,&nbsp;Walaa A. Alshahrani ,&nbsp;Ghaida K. Alhathlol ,&nbsp;Fatimah Alsheikh ,&nbsp;Abdulaziz Alakeel ,&nbsp;Majed S. Al Yami ,&nbsp;Mohammad Fouda ,&nbsp;Omar A. Almohammed ,&nbsp;Meshal S. Alhamed ,&nbsp;Awatif Hafiz ,&nbsp;Hussam Kutbi ,&nbsp;Alaa Bagalagel ,&nbsp;Aisha Alharbi ,&nbsp;Mashael Alaboud ,&nbsp;Sarah Aljohani ,&nbsp;Waddah Ashram","doi":"10.1016/j.jsps.2024.102203","DOIUrl":"10.1016/j.jsps.2024.102203","url":null,"abstract":"<div><h3>Introduction</h3><div>Evolocumab’s short-term efficacy and safety were proven in phase-3 clinical trial, but its long-term safety and effectiveness in the Saudi population are yet to be studied. The aim of this study was to assess the long-term safety and effectiveness of evolocumab in Saudi patients with primary hypercholesterolemia or mixed dyslipidemia.</div></div><div><h3>Method</h3><div>A retrospective cohort study evaluated adult patients who had newly been prescribed evolocumab for hypercholesterolemia or mixed dyslipidemia. Safety events included myocardial infarction, unstable angina, stroke, transient ischemic attack, heart failure, rhabdomyolysis, renal dysfunction, and myalgia. Effectiveness outcomes included changes in lipid profiles from baseline, assessed at 6-, 12-, 18-, and 24-month.</div></div><div><h3>Results</h3><div>The study sample were 469 who newly prescribed evolocumab, from which 69.1 % being male, were included. The most prevalent comorbidities were coronary artery disease, diabetes, and hypertension. Statin was the most commonly used therapy. The most common adverse events at 6-month follow-up, based on the incidence rate per 1000 person-years, were coronary revascularization (63.20), myalgia (44.96), myocardial infarction (31.53), unstable angina (31.49), heart failure (26.94), rhabdomyolysis without renal dysfunction (8.93), transient ischemic attack (4.46), and rhabdomyolysis with renal dysfunction (4.46). Stroke incidence increased with follow-up length, from 8.87 per 1000 person-years at 6 months to 12.84 per 1000 person-years at 24 months. Evolocumab use significantly reduced LDL and total cholesterol levels at 6, 12, 18, and 24 months follow-up, while having no significant effect on HDL or triglycerides levels.</div></div><div><h3>Conclusion</h3><div>Evolocumab appeared to be safe and effective therapeutic option for patients with primary hypercholesterolemia or mixed dyslipidemia to potentially reduce LDL levels to therapeutic levels when statins are insufficient.</div></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 12","pages":"Article 102203"},"PeriodicalIF":3.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Otostegia fruticosa (Forssk.) – A comprehensive insight of its ethnopharmacology, phytochemistry, and pharmacological activities Otostegia fruticosa (Forssk.) - 对其民族药理学、植物化学和药理活性的全面了解
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-01 DOI: 10.1016/j.jsps.2024.102189
Mohammed F. Hawwal , Sarfaraz Ahmed , Perwez Alam , Omer I. Fantoukh , Gadah A. AlHamoud , Hattan A. Alharbi , Waleed A. Alobaid , Hanan Khojah
Otostegia fruticosa (Forssk.) is a shrub of the Lamiaceae family with a wide geographic distribution in Saudi Arabia, Western and Eastern Africa, Ethiopia, and the Middle East. The current study provides an overview of recent developments in the knowledge of O. fruticosa’s ethnobotanical, pharmacological, and phytochemical properties. In folkloric medicine, it has been used since ancient times for gastrointestinal disorders, oral health, ocular irritation, antiparasitic, diarrhea, tonsillitis, arthritis, respiratory complications, and sunstroke treatment. Pharmacological investigations of its antibacterial, antioxidant, anti-inflammatory, cytotoxic, analgesic, larvicidal, nephroprotective, and other effects further validated its folklore practice. A range of diterpenoids, triterpenes, flavonoids, and essential oils have been found in O. fruticosa, according to phytochemical studies, which are thought to be responsible for the pharmacological effects of this plant species. This scientific review summarizes the most important secondary metabolites isolated from the O. fruticosa. It also summarizes the biological activities, providing insights into further scientific exploration.
Otostegia fruticosa(Forssk.)是一种唇形科灌木,广泛分布于沙特阿拉伯、非洲西部和东部、埃塞俄比亚和中东地区。目前的研究概述了有关 O. fruticosa 的民族植物学、药理学和植物化学特性的最新进展。在民间医药中,它自古以来就被用于治疗胃肠道疾病、口腔健康、眼部刺激、抗寄生虫、腹泻、扁桃体炎、关节炎、呼吸系统并发症和中暑。对其抗菌、抗氧化、抗炎、细胞毒性、镇痛、杀幼虫、保护肾脏等功效的药理研究进一步验证了其民间做法。根据植物化学研究发现,O. fruticosa 中含有一系列二萜类、三萜类、黄酮类和精油,这些物质被认为是该植物物种药理作用的主要成分。这篇科学综述总结了从 O. fruticosa 分离出来的最重要的次生代谢物。它还总结了其生物活性,为进一步的科学探索提供了启示。
{"title":"Otostegia fruticosa (Forssk.) – A comprehensive insight of its ethnopharmacology, phytochemistry, and pharmacological activities","authors":"Mohammed F. Hawwal ,&nbsp;Sarfaraz Ahmed ,&nbsp;Perwez Alam ,&nbsp;Omer I. Fantoukh ,&nbsp;Gadah A. AlHamoud ,&nbsp;Hattan A. Alharbi ,&nbsp;Waleed A. Alobaid ,&nbsp;Hanan Khojah","doi":"10.1016/j.jsps.2024.102189","DOIUrl":"10.1016/j.jsps.2024.102189","url":null,"abstract":"<div><div>Otostegia fruticosa<!--> <!-->(Forssk.) is a shrub of the Lamiaceae family with a wide geographic distribution in Saudi Arabia, Western and Eastern Africa, Ethiopia, and the Middle East. The current study provides an overview of recent developments in the knowledge of<!--> <em>O. fruticosa</em>’s<!--> <!-->ethnobotanical, pharmacological, and phytochemical properties. In folkloric medicine, it has been used since ancient times for gastrointestinal disorders, oral health, ocular irritation, antiparasitic, diarrhea, tonsillitis, arthritis, respiratory complications, and sunstroke treatment. Pharmacological investigations of its antibacterial, antioxidant, anti-inflammatory, cytotoxic, analgesic, larvicidal, nephroprotective, and other effects further validated its folklore practice. A range of diterpenoids, triterpenes, flavonoids, and essential oils have been found in<!--> <em>O. fruticosa</em>, according to phytochemical studies, which are thought to be responsible for the pharmacological effects of this plant species. This scientific review summarizes the most important secondary metabolites isolated from the <em>O</em>. <em>fruticosa</em>. It also summarizes the biological activities, providing insights into further scientific exploration.</div></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 11","pages":"Article 102189"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142554976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytochrome c and cancer cell metabolism: A new perspective 细胞色素 c 与癌细胞代谢:新视角
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-31 DOI: 10.1016/j.jsps.2024.102194
Bader Alshehri
Cytochrome c is a vital electron carrier in the mitochondrial respiratory chain. When the outer membrane of mitochondria becomes permeable, cytochrome c is discharged into the cytoplasm, where it initiates the intrinsic apoptosis pathway. The complex interaction between cytochrome c and apoptosis protease-activating factor-1 (Apaf-1) leads to the formation of the apoptosome and activation of a cascade of caspases, highlighting the critical role of cytochrome c in controlling cell death mechanisms. Additionally, cytochrome c undergoes post-translational modifications, especially phosphorylation, which intricately regulate its roles in both respiration and apoptosis. These modifications add layers of complexity to how cytochrome c effectively controls cellular functions. cytochrome c becomes a lighthouse in the intricate web of cancer, its expression patterns providing hints about prognosis and paths toward treatment. Reduced levels of cytochrome c have been observed in cancer tissues, indicating a potential inhibition of apoptosis. For instance, in glioma tissues, cytochrome c levels were lower compared to healthy tissues, and this reduction became more pronounced in advanced stages of the disease. However, the role of cytochrome c in cancer becomes more intricate as it becomes intertwined with the metabolic reprogramming of cancer cells. This suggests that cytochrome c plays a crucial role in tumor progression and resistance to treatment. Viewing cytochrome c as a molecular mosaic reveals that it is not merely a protein, but also a central player in determining cellular fate. This realization opens up exciting avenues for potential advancements in cancer diagnosis and treatment strategies. Despite the advancements made, the narrative surrounding cytochrome c remains incomplete, urging further exploration into its complexities and the biological implications linked to cancer. cytochrome c stands as a beacon of hope and a promising target for therapy in the battle against cancer, particularly due to its significant involvement in tumor metabolism. It holds the potential for a future where innovative solutions can be developed to address the intricate challenges of cellular fate. In this review, we have endeavored to illuminate the multifaceted domain of cytochrome c drawing connections among apoptosis, metabolic reprogramming, and the Warburg effect in the context of cancer.
细胞色素 c 是线粒体呼吸链中的重要电子载体。当线粒体外膜发生渗透时,细胞色素 c 就会被释放到细胞质中,从而启动内在凋亡途径。细胞色素 c 与凋亡蛋白酶激活因子-1(Apaf-1)之间的复杂相互作用导致凋亡小体的形成和 caspases 级联反应的激活,从而凸显了细胞色素 c 在控制细胞死亡机制中的关键作用。此外,细胞色素 c 还会发生翻译后修饰,特别是磷酸化,从而错综复杂地调节其在呼吸和细胞凋亡中的作用。这些修饰使细胞色素 c 如何有效控制细胞功能变得更加复杂。细胞色素 c 成为癌症复杂网络中的灯塔,其表达模式为预后和治疗提供了提示。在癌症组织中观察到细胞色素 c 水平降低,这表明细胞凋亡可能受到抑制。例如,在胶质瘤组织中,细胞色素 c 的水平比健康组织低,这种降低在疾病晚期更为明显。然而,细胞色素 c 在癌症中的作用变得更加复杂,因为它与癌细胞的代谢重编程交织在一起。这表明,细胞色素 c 在肿瘤进展和抗药性方面起着至关重要的作用。将细胞色素 c 看作分子马赛克揭示了它不仅仅是一种蛋白质,还是决定细胞命运的核心角色。这一认识为癌症诊断和治疗策略的潜在进步开辟了令人兴奋的途径。尽管取得了进展,但围绕细胞色素 c 的叙述仍不完整,这就需要进一步探索其复杂性以及与癌症相关的生物学意义。细胞色素 c 是抗击癌症的希望灯塔和有前途的治疗目标,特别是因为它在肿瘤代谢中的重要作用。在未来,细胞色素 c 具有开发创新解决方案的潜力,以应对细胞命运的复杂挑战。在这篇综述中,我们试图阐明细胞色素 c 的多面性,并在癌症的背景下将细胞凋亡、新陈代谢重编程和沃伯格效应联系起来。
{"title":"Cytochrome c and cancer cell metabolism: A new perspective","authors":"Bader Alshehri","doi":"10.1016/j.jsps.2024.102194","DOIUrl":"10.1016/j.jsps.2024.102194","url":null,"abstract":"<div><div>Cytochrome <em>c</em> is a vital electron carrier in the mitochondrial respiratory chain. When the outer membrane of mitochondria becomes permeable, cytochrome <em>c</em> is discharged into the cytoplasm, where it initiates the intrinsic apoptosis pathway. The complex interaction between cytochrome <em>c</em> and apoptosis protease-activating factor-1 (Apaf-1) leads to the formation of the apoptosome and activation of a cascade of caspases, highlighting the critical role of cytochrome <em>c</em> in controlling cell death mechanisms. Additionally, cytochrome <em>c</em> undergoes post-translational modifications, especially phosphorylation, which intricately regulate its roles in both respiration and apoptosis. These modifications add layers of complexity to how cytochrome <em>c</em> effectively controls cellular functions. cytochrome <em>c</em> becomes a lighthouse in the intricate web of cancer, its expression patterns providing hints about prognosis and paths toward treatment. Reduced levels of cytochrome <em>c</em> have been observed in cancer tissues, indicating a potential inhibition of apoptosis. For instance, in glioma tissues, cytochrome <em>c</em> levels were lower compared to healthy tissues, and this reduction became more pronounced in advanced stages of the disease. However, the role of cytochrome <em>c</em> in cancer becomes more intricate as it becomes intertwined with the metabolic reprogramming of cancer cells. This suggests that cytochrome <em>c</em> plays a crucial role in tumor progression and resistance to treatment. Viewing cytochrome <em>c</em> as a molecular mosaic reveals that it is not merely a protein, but also a central player in determining cellular fate. This realization opens up exciting avenues for potential advancements in cancer diagnosis and treatment strategies. Despite the advancements made, the narrative surrounding cytochrome <em>c</em> remains incomplete, urging further exploration into its complexities and the biological implications linked to cancer. cytochrome <em>c</em> stands as a beacon of hope and a promising target for therapy in the battle against cancer, particularly due to its significant involvement in tumor metabolism. It holds the potential for a future where innovative solutions can be developed to address the intricate challenges of cellular fate. In this review, we have endeavored to illuminate the multifaceted domain of cytochrome <em>c</em> drawing connections among apoptosis, metabolic reprogramming, and the Warburg effect in the context of cancer.</div></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 12","pages":"Article 102194"},"PeriodicalIF":3.0,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rise of implantable drugs: A chronicle of breakthroughs in drug delivery systems 植入式药物的兴起:给药系统突破纪事
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-30 DOI: 10.1016/j.jsps.2024.102193
Kampanart Huanbutta , Vivek Puri , Ameya Sharma , Inderbir Singh , Pornsak Sriamornsak , Tanikan Sangnim
In recent years, implantable drug delivery systems (IDDSs) have undergone significant advancements because they offer many advantages to patients and health care professionals. Miniaturization has reduced the size of these devices, making them less invasive and easier to implant. Remote control provides more precise medication delivery and dosage. Biodegradable implants are an additional advancement in implantable drug delivery systems that eliminate the need for surgical removal. Smart implants can monitor a patient’s condition and adjust their drug doses. Long-acting implants also provide sustained drug delivery for months or even years, eliminating the need for regular medication dosing, and wireless power and data transmission technology enables the use of devices that are more comfortable and less invasive. These innovations have enhanced patient outcomes by enabling more precise administration, sustained drug delivery, and improved health care monitoring. With continued research and development, it is anticipated that IDDSs will become more effective and provide patients with improved health outcomes. This review categorizes and discusses the benefits and limitations of recent novel IDDSs for their potential therapeutic use.
近年来,植入式给药系统(IDDS)取得了长足的进步,因为它们为患者和医护人员提供了许多优势。微型化缩小了这些设备的尺寸,使其创伤更小、更易于植入。远程控制可提供更精确的给药和剂量。生物可降解植入体是植入式给药系统的又一进步,无需手术取出。智能植入体可以监测病人的病情并调整药物剂量。长效植入体还能持续给药数月甚至数年,无需定期服药,而无线供电和数据传输技术则使设备的使用更舒适、创伤更小。这些创新技术通过实现更精确的给药、持续给药和更好的医疗监测,提高了患者的治疗效果。随着研究和开发的不断深入,预计 IDDS 将变得更加有效,并为患者提供更好的医疗效果。本综述对最近出现的新型 IDDS 进行了分类,并讨论了其潜在治疗用途的优点和局限性。
{"title":"Rise of implantable drugs: A chronicle of breakthroughs in drug delivery systems","authors":"Kampanart Huanbutta ,&nbsp;Vivek Puri ,&nbsp;Ameya Sharma ,&nbsp;Inderbir Singh ,&nbsp;Pornsak Sriamornsak ,&nbsp;Tanikan Sangnim","doi":"10.1016/j.jsps.2024.102193","DOIUrl":"10.1016/j.jsps.2024.102193","url":null,"abstract":"<div><div>In recent years, implantable drug delivery systems (IDDSs) have undergone significant advancements because they offer many advantages to patients and health care professionals. Miniaturization has reduced the size of these devices, making them less invasive and easier to implant. Remote control provides more precise medication delivery and dosage. Biodegradable implants are an additional advancement in implantable drug delivery systems that eliminate the need for surgical removal. Smart implants can monitor a patient’s condition and adjust their drug doses. Long-acting implants also provide sustained drug delivery for months or even years, eliminating the need for regular medication dosing, and wireless power and data transmission technology enables the use of devices that are more comfortable and less invasive. These innovations have enhanced patient outcomes by enabling more precise administration, sustained drug delivery, and improved health care monitoring. With continued research and development, it is anticipated that IDDSs will become more effective and provide patients with improved health outcomes. This review categorizes and discusses the benefits and limitations of recent novel IDDSs for their potential therapeutic use.</div></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 12","pages":"Article 102193"},"PeriodicalIF":3.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142577458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic review of obesity burden in Saudi Arabia: Prevalence and associated co-morbidities 沙特阿拉伯肥胖负担的系统回顾:患病率及相关并发症
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-24 DOI: 10.1016/j.jsps.2024.102192
Hussain A. Al-Omar , Ali Alshehri , Saleh A. Alqahtani , Hana Alabdulkarim , Ali Alrumaih , Mahmoud S. Eldin

Introduction

Saudi Arabia has experienced an increasing trend in obesity prevalence in the last three decades; obesity is a significant risk factor for non-communicable diseases, which may cause healthcare and economic burdens. In this systematic review, we aim to explore the obesity prevalence, obesity-related complications (ORCs), and the economic burden of obesity in Saudi Arabia.

Methods

Literature searches for relevant local studies across Saudi Arabia spanning 2012 to 2022 were performed in PubMed and EMBASE, along with supplementary searches for relevant congress abstracts. Only studies that discussed obesity prevalence in Saudi Arabia in relation to any gender or age group, the prevalence of ORCs in Saudi Arabia for any gender or age group, and/or the economic burden of obesity and how it impacts the healthcare system in Saudi Arabia, and were published in the English language, were selected for inclusion. No age or gender restrictions were imposed.

Results

The prevalence of obesity in Saudi Arabia ranged from 20% to 39% and up to 19.4% among adults and adolescents, respectively. The most reported ORCs were hypertension (67.6%), type 2 diabetes (60.7%), and hypercholesterolaemia (51.3%), and an association between obesity and ORCs was established, showing an increased risk with increasing body mass index. The economic burden of obesity across Saudi Arabia was estimated to be 6.4 billion US dollars (USD) for treatment and management.

Conclusion

Obesity affects a substantial proportion of the Saudi general population and is a significant burden on individuals, as demonstrated by the prevalence of ORCs. Multifaceted, short- and long-term approaches involving interventions that operate at multiple levels and target both individuals and communities are urgently needed; there is a particular need for a national strategy and a specific, systems-based policy. Further research will help increase awareness of obesity and its management, which will be crucial for transforming the healthcare system under Vision 2030.
导言沙特阿拉伯在过去三十年中肥胖症发病率呈上升趋势;肥胖症是非传染性疾病的重要风险因素,可能会造成医疗保健和经济负担。在这篇系统性综述中,我们旨在探讨沙特阿拉伯的肥胖患病率、肥胖相关并发症(ORCs)以及肥胖造成的经济负担。方法我们在 PubMed 和 EMBASE 中检索了 2012 年至 2022 年期间沙特阿拉伯当地的相关研究,并补充检索了相关的大会摘要。只有讨论沙特阿拉伯任何性别或年龄组的肥胖患病率、沙特阿拉伯任何性别或年龄组的ORC患病率、和/或肥胖的经济负担及其如何影响沙特阿拉伯的医疗保健系统,并以英语发表的研究才被选入。结果沙特阿拉伯成年人和青少年的肥胖患病率分别为 20% 至 39%,最高达 19.4%。报告最多的器官功能障碍是高血压(67.6%)、2 型糖尿病(60.7%)和高胆固醇血症(51.3%),肥胖与器官功能障碍之间存在关联,表明随着体重指数的增加,风险也会增加。据估计,沙特阿拉伯全国因肥胖症造成的治疗和管理经济负担达 64 亿美元。亟需采取多方面、短期和长期的方法,在多个层面开展针对个人和社区的干预活动;尤其需要制定国家战略和以系统为基础的具体政策。进一步的研究将有助于提高人们对肥胖症及其管理的认识,这对于根据《2030 年远景规划》转变医疗保健系统至关重要。
{"title":"A systematic review of obesity burden in Saudi Arabia: Prevalence and associated co-morbidities","authors":"Hussain A. Al-Omar ,&nbsp;Ali Alshehri ,&nbsp;Saleh A. Alqahtani ,&nbsp;Hana Alabdulkarim ,&nbsp;Ali Alrumaih ,&nbsp;Mahmoud S. Eldin","doi":"10.1016/j.jsps.2024.102192","DOIUrl":"10.1016/j.jsps.2024.102192","url":null,"abstract":"<div><h3>Introduction</h3><div>Saudi Arabia has experienced an increasing trend in obesity prevalence in the last three decades; obesity is a significant risk factor for non-communicable diseases, which may cause healthcare and economic burdens. In this systematic review, we aim to explore the obesity prevalence, obesity-related complications (ORCs), and the economic burden of obesity in Saudi Arabia.</div></div><div><h3>Methods</h3><div>Literature searches for relevant local studies across Saudi Arabia spanning 2012 to 2022 were performed in PubMed and EMBASE, along with supplementary searches for relevant congress abstracts. Only studies that discussed obesity prevalence in Saudi Arabia in relation to any gender or age group, the prevalence of ORCs in Saudi Arabia for any gender or age group, and/or the economic burden of obesity and how it impacts the healthcare system in Saudi Arabia, and were published in the English language, were selected for inclusion. No age or gender restrictions were imposed.</div></div><div><h3>Results</h3><div>The prevalence of obesity in Saudi Arabia ranged from 20% to 39% and up to 19.4% among adults and adolescents, respectively. The most reported ORCs were hypertension (67.6%), type 2 diabetes (60.7%), and hypercholesterolaemia (51.3%), and an association between obesity and ORCs was established, showing an increased risk with increasing body mass index. The economic burden of obesity across Saudi Arabia was estimated to be 6.4 billion US dollars (USD) for treatment and management.</div></div><div><h3>Conclusion</h3><div>Obesity affects a substantial proportion of the Saudi general population and is a significant burden on individuals, as demonstrated by the prevalence of ORCs. Multifaceted, short- and long-term approaches involving interventions that operate at multiple levels and target both individuals and communities are urgently needed; there is a particular need for a national strategy and a specific, systems-based policy. Further research will help increase awareness of obesity and its management, which will be crucial for transforming the healthcare system under <span><span>Vision 2030</span></span>.</div></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 11","pages":"Article 102192"},"PeriodicalIF":3.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142535929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Captagon: A comprehensive bibliometric analysis (1962–2024) of its global impact, health and mortality risks Captagon:对其全球影响、健康和死亡风险的综合文献计量分析(1962-2024 年
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-22 DOI: 10.1016/j.jsps.2024.102188
Seraphina Fong , Alessandro Carollo , Andrea Rossato , Elisabeth Prevete , Gianluca Esposito , Ornella Corazza
Captagon is a synthetic stimulant combining amphetamine and theophylline. Initially introduced in 1961 as a treatment for hyperactivity, depression, and narcolepsy, Captagon was later classified as a Schedule 1 controlled substance due to its addictive and hallucinogenic properties. Despite its global prohibition in 1986, the trade of counterfeit products is widespread, especially in south-east Europe and far-east Asia, with its production being on the rise in Middle Eastern regions. This paper presents a quantitative data-driven bibliometric analysis of the existing literature on Captagon up to July 2024. It aims to delineate the structure and development of knowledge surrounding the substance, including key contributing countries, authors, prominent sources, and recurring thematic keywords. The quantitative and data-driven results were then used to guide the narrative discussion on Captagon. Findings indicate that current research predominantly focuses on Captagon’s use and impact in conflict zones, often exploring its interaction with other substances used by civilians and militias. Results also show a growing trend in Captagon research, with Saudi Arabia, Jordan, and Iraq emerging as main contributors to the literature. Despite the attention in specific regions, a considerable gap remains in understanding the mechanisms of action of Captagon (particularly regarding its metabolism, toxicology, mortality risk), and in developing protocols for its discontinuation. Additionally, the drug’s inconsistent composition requires further analyses to better predict risks and establish effective management strategies. Addressing these gaps will be crucial for the development of novel interventions and policies to mitigate the adverse effects of Captagon and improve public health systems worldwide.
卡普他酮是一种结合了苯丙胺和茶碱的合成兴奋剂。Captagon 最初于 1961 年问世,用于治疗多动症、抑郁症和嗜睡症,后因其成瘾和致幻特性被列为附表 1 受控物质。尽管 Captagon 于 1986 年被全球禁用,但假冒产品的交易却非常普遍,尤其是在东南欧和远东亚洲,中东地区的生产量也在不断上升。本文对截至 2024 年 7 月有关 Captagon 的现有文献进行了定量数据驱动的文献计量分析。其目的是勾勒出围绕该物质的知识结构和发展,包括主要贡献国、作者、主要来源和重复出现的主题关键词。定量和数据驱动的结果随后被用于指导有关 Captagon 的叙述性讨论。研究结果表明,目前的研究主要侧重于 Captagon 在冲突地区的使用和影响,通常探讨其与平民和民兵使用的其他物质之间的相互作用。研究结果还显示出 Captagon 研究的增长趋势,沙特阿拉伯、约旦和伊拉克成为文献的主要贡献者。尽管特定地区的研究备受关注,但在了解 Captagon 的作用机制(特别是其代谢、毒理学、死亡风险)和制定停药方案方面仍存在相当大的差距。此外,还需要进一步分析该药物不一致的成分,以便更好地预测风险和制定有效的管理策略。缩小这些差距对于制定新型干预措施和政策以减轻 Captagon 的不良影响并改善全球公共卫生系统至关重要。
{"title":"Captagon: A comprehensive bibliometric analysis (1962–2024) of its global impact, health and mortality risks","authors":"Seraphina Fong ,&nbsp;Alessandro Carollo ,&nbsp;Andrea Rossato ,&nbsp;Elisabeth Prevete ,&nbsp;Gianluca Esposito ,&nbsp;Ornella Corazza","doi":"10.1016/j.jsps.2024.102188","DOIUrl":"10.1016/j.jsps.2024.102188","url":null,"abstract":"<div><div>Captagon is a synthetic stimulant combining amphetamine and theophylline. Initially introduced in 1961 as a treatment for hyperactivity, depression, and narcolepsy, Captagon was later classified as a Schedule 1 controlled substance due to its addictive and hallucinogenic properties. Despite its global prohibition in 1986, the trade of counterfeit products is widespread, especially in south-east Europe and far-east Asia, with its production being on the rise in Middle Eastern regions. This paper presents a quantitative data-driven bibliometric analysis of the existing literature on Captagon up to July 2024. It aims to delineate the structure and development of knowledge surrounding the substance, including key contributing countries, authors, prominent sources, and recurring thematic keywords. The quantitative and data-driven results were then used to guide the narrative discussion on Captagon. Findings indicate that current research predominantly focuses on Captagon’s use and impact in conflict zones, often exploring its interaction with other substances used by civilians and militias. Results also show a growing trend in Captagon research, with Saudi Arabia, Jordan, and Iraq emerging as main contributors to the literature. Despite the attention in specific regions, a considerable gap remains in understanding the mechanisms of action of Captagon (particularly regarding its metabolism, toxicology, mortality risk), and in developing protocols for its discontinuation. Additionally, the drug’s inconsistent composition requires further analyses to better predict risks and establish effective management strategies. Addressing these gaps will be crucial for the development of novel interventions and policies to mitigate the adverse effects of Captagon and improve public health systems worldwide.</div></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 11","pages":"Article 102188"},"PeriodicalIF":3.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142535928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacological investigations of newly synthesized oxazolones and imidazolones as COX-2 inhibitors 作为 COX-2 抑制剂的新合成噁唑酮和咪唑酮的药理研究
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-19 DOI: 10.1016/j.jsps.2024.102191
Iqra Saleem Naz Babari , Muhammad Islam , Hamid Saeed , Humaira Nadeem , Hassaan Anwer Rathore
Oxazoles and Imidazoles are heterocyclic compounds with significant biological activities. The present study explores the pharmacological effects of some new oxazole and imidazole derivatives as potential COX-2 inhibitors. Docking studies of the compounds against targeted proteins COX-2 and TACE manifested good binding affinities for both the targets supporting their anti-inflammatory potential. Compounds (3F-A, 3F-B, N-A, N-B) were evaluated for in vivo anti-inflammatory effects by carrageenan-induced paw edema. Among all, compound N-A was found to be the most effective as it displayed most pronounced reduction in inflammation that was comparable to indomethacin. The in vivo tissue antioxidant activity was performed for estimation of the level of catalase, GSH, GST, and thiobarbituric acid in paw tissue. The results exhibited that targeted compounds improved the oxidative stress and restored the expression of enzymes. H &E staining revealed that aforesaid compounds displayed well-defined restoration of cellular damage. Compound NA exhibited maximum structural and functional preservation. Reduction in the expression of inflammatory markers was also analyzed by ELISA and maximum reduction in protein expression (COX-2 and TNF-a) was observed for compound N-B. Quantification of mRNA was done using PCR and a decrease in the expression of COX-2 mRNA level in treatment groups was depicted by all the new compounds but N-B showed maximum reduction in enzyme expression. All the results obtained from the present study have shown the significant anti-inflammatory potential of new compounds via the COX-2 inhibition pathway.
噁唑和咪唑是具有重要生物活性的杂环化合物。本研究探讨了一些新的噁唑和咪唑衍生物作为潜在 COX-2 抑制剂的药理作用。这些化合物与靶蛋白 COX-2 和 TACE 的对接研究表明,它们与这两个靶蛋白都有很好的结合亲和力,支持它们的抗炎潜力。通过卡拉胶诱导的爪水肿评估了化合物(3F-A、3F-B、N-A、N-B)的体内抗炎作用。结果发现,在所有化合物中,化合物 N-A 的消炎效果最明显,与吲哚美辛相当。体内组织抗氧化活性是通过评估爪组织中过氧化氢酶、谷胱甘肽、谷胱甘肽和硫代巴比妥酸的水平来实现的。结果显示,靶向化合物改善了氧化应激,恢复了酶的表达。Hamp;E 染色显示,上述化合物对细胞损伤有明确的修复作用。化合物 NA 表现出最大程度的结构和功能保护。还通过 ELISA 分析了炎症标志物表达的减少情况,发现化合物 N-B 蛋白表达(COX-2 和 TNF-a)的减少幅度最大。利用 PCR 对 mRNA 进行了定量分析,结果显示,所有新化合物都降低了处理组中 COX-2 mRNA 的表达水平,但 N-B 的酶表达降低幅度最大。本研究的所有结果都表明,新化合物通过 COX-2 抑制途径具有显著的抗炎潜力。
{"title":"Pharmacological investigations of newly synthesized oxazolones and imidazolones as COX-2 inhibitors","authors":"Iqra Saleem Naz Babari ,&nbsp;Muhammad Islam ,&nbsp;Hamid Saeed ,&nbsp;Humaira Nadeem ,&nbsp;Hassaan Anwer Rathore","doi":"10.1016/j.jsps.2024.102191","DOIUrl":"10.1016/j.jsps.2024.102191","url":null,"abstract":"<div><div>Oxazoles and Imidazoles are heterocyclic compounds with significant biological activities. The present study explores the pharmacological effects of some new oxazole and imidazole derivatives as potential COX-2 inhibitors. Docking studies of the compounds against targeted proteins COX-2 and TACE manifested good binding affinities for both the targets supporting their anti-inflammatory potential. Compounds (3F-A, 3F-B, N-A, N-B) were evaluated for <em>in vivo</em> anti-inflammatory effects by carrageenan-induced paw edema. Among all, compound N-A was found to be the most effective as it displayed most pronounced reduction in inflammation that was comparable to indomethacin. The <em>in vivo</em> tissue antioxidant activity was performed for estimation of the level of catalase, GSH, GST, and thiobarbituric acid in paw tissue. The results exhibited that targeted compounds improved the oxidative stress and restored the expression of enzymes. H &amp;E staining revealed that aforesaid compounds displayed well-defined restoration of cellular damage. Compound NA exhibited maximum structural and functional preservation. Reduction in the expression of inflammatory markers was also analyzed by ELISA and maximum reduction in protein expression (COX-2 and TNF-a) was observed for compound N-B. Quantification of mRNA was done using PCR and a decrease in the expression of COX-2 mRNA level in treatment groups was depicted by all the new compounds but N-B showed maximum reduction in enzyme expression. All the results obtained from the present study have shown the significant anti-inflammatory potential of new compounds via the COX-2 inhibition pathway.</div></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 11","pages":"Article 102191"},"PeriodicalIF":3.0,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142535934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Saudi Pharmaceutical Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1